Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03524430 · ClinicalTrials.gov registry record · NA

RNA Disruption Assay (RDA)-Breast Cancer Response Evaluation for Individualized Therapy

A NA study of Breast Neoplasm Female, sponsored by Rna Diagnostics.

Recruiting
Registry status
NA
Development phase
801
Enrollment target
7
Study locations

NCT03524430 is a NA study of Breast Neoplasm Female that is actively recruiting participants, run by Rna Diagnostics. The registered enrollment target is 801 participants, above the 80-participant average among 8 other Breast Neoplasm Female trials with a reported enrollment target (901% higher). The trial reports 7 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03524430, a NA study of Breast Neoplasm Female, is actively recruiting participants, sponsored by Rna Diagnostics.

RECRUITING
Registry status
NA
Development phase
801 participants
Enrollment target
7
Study locations

Study Summary

The current study aims to provide validation results of RNA Disruption Assay (RDA) as a tumour response assessment tool that uses tumour core biopsies taken starting from 35 +/- 4 days after the initiation of neoadjuvant chemotherapy.

Conditions Studied

Breast Neoplasm Female

Interventions

  • PROCEDURE Core needle biopsy

Study Locations (7)

Other

  • Sunnybrook Health Sciences Center - Toronto
  • Institut de Cancerologie de Strasbourg - Strasbourg
  • Universitätsklinikum Münster - Münster
  • SST di Cremona Multidisciplinare di Patologia Mammaria, Italy - Cremona
  • NZOZ Neuromed - Lublin
  • Hospital U. 12 de Octubre - Madrid

Missouri

  • Siteman Cancer Center - St Louis

Trial Details

FieldValue
Enrollment Target 801 participants
Start Date 2018-04-26
Est. Completion 2031-03-31
Phase NA

Sponsor

Rna Diagnostics

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03524430

The ClinicalTrials.gov registry entry for NCT03524430 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 801 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 80-participant average among 8 other Breast Neoplasm Female trials with a reported enrollment target (901% higher). The listed sponsor is Rna Diagnostics, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Breast Neoplasm Female appearing as the primary indexed condition, and to 1 intervention - of which Core needle biopsy is the first listed.

NCT03524430 reports 7 study locations spanning 2 distinct geographic areas - top geographies include Other, Missouri.

Frequently Asked Questions

What is clinical trial NCT03524430 about?

NCT03524430 is a clinical study titled "RNA Disruption Assay (RDA)-Breast Cancer Response Evaluation for Individualized Therapy". The current study aims to provide validation results of RNA Disruption Assay (RDA) as a tumour response assessment tool that uses tumour core biopsies taken starting from 35 +/- 4 days after the initiation of neoadjuvant chemotherapy.

What is the current status of trial NCT03524430?

This trial is currently recruiting. It is a NA study. The enrollment target is 801 participants. The study started on 2018-04-26. Estimated completion is 2031-03-31.

What conditions does trial NCT03524430 study?

This clinical trial studies the following conditions: Breast Neoplasm Female.

What interventions are being tested in trial NCT03524430?

The interventions under investigation include: Core needle biopsy (PROCEDURE).

Who is sponsoring clinical trial NCT03524430?

This trial is sponsored by Rna Diagnostics, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03524430 being conducted?

This trial has 7 study locations across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Neoplasm Female

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Breast Neoplasm Female

All registered trials for this condition

Missouri

All trials with a study site in Missouri

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.